BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zenych A, Fournier L, Chauvierre C. Nanomedicine progress in thrombolytic therapy. Biomaterials 2020;258:120297. [DOI: 10.1016/j.biomaterials.2020.120297] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Almalki WH, Alghamdi S, Alzahrani A, Zhang W. Emerging paradigms in treating cerebral infarction with nanotheranostics: opportunities and clinical challenges. Drug Discov Today 2021;26:826-35. [PMID: 33383212 DOI: 10.1016/j.drudis.2020.12.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Huang H, Feng W, Chen Y. Two-dimensional biomaterials: material science, biological effect and biomedical engineering applications. Chem Soc Rev 2021;50:11381-485. [PMID: 34661206 DOI: 10.1039/d0cs01138j] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Wang Z, Huang H, Chen Y, Zheng Y. Current Strategies for Microbubble-Based Thrombus Targeting: Activation-Specific Epitopes and Small Molecular Ligands. Front Bioeng Biotechnol 2021;9:699450. [PMID: 34336810 DOI: 10.3389/fbioe.2021.699450] [Reference Citation Analysis]
4 Chang LH, Chuang EY, Cheng TM, Lin C, Shih CM, Wu AT, Jheng PR, Lu HY, Shih CC, Mi FL. Thrombus-specific theranostic nanocomposite for codelivery of thrombolytic drug, algae-derived anticoagulant and NIR fluorescent contrast agent. Acta Biomater 2021:S1742-7061(21)00510-9. [PMID: 34358695 DOI: 10.1016/j.actbio.2021.07.072] [Reference Citation Analysis]
5 Zhang Y, Liu Y, Zhang T, Wang Q, Huang L, Zhong Z, Lin J, Hu K, Xin H, Wang X. Targeted Thrombolytic Therapy with Metal-Organic-Framework-Derived Carbon Based Platforms with Multimodal Capabilities. ACS Appl Mater Interfaces 2021;13:24453-62. [PMID: 34008940 DOI: 10.1021/acsami.1c03134] [Reference Citation Analysis]
6 Wang L, Wang J, Hao J, Dong Z, Wu J, Shen G, Ying T, Feng L, Cai X, Liu Z, Zheng Y. Guiding Drug Through Interrupted Bloodstream for Potentiated Thrombolysis by C-Shaped Magnetic Actuation System In Vivo. Adv Mater 2021;33:e2105351. [PMID: 34647345 DOI: 10.1002/adma.202105351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Guan Q, Dou H. Thrombus-Targeting Polymeric Nanocarriers and Their Biomedical Applications in Thrombolytic Therapy. Front Physiol 2021;12:763085. [PMID: 34916956 DOI: 10.3389/fphys.2021.763085] [Reference Citation Analysis]
8 Gauberti M, Martinez de Lizarrondo S, Vivien D. Thrombolytic strategies for ischemic stroke in the thrombectomy era. J Thromb Haemost 2021;19:1618-28. [PMID: 33834615 DOI: 10.1111/jth.15336] [Reference Citation Analysis]
9 Bernardo-Castro S, Albino I, Barrera-Sandoval ÁM, Tomatis F, Sousa JA, Martins E, Simões S, Lino MM, Ferreira L, Sargento-Freitas J. Therapeutic Nanoparticles for the Different Phases of Ischemic Stroke. Life (Basel) 2021;11:482. [PMID: 34073229 DOI: 10.3390/life11060482] [Reference Citation Analysis]
10 González-Félix MA, Mejía-Manzano LA, González-Valdez J. Biological nanoparticles: Relevance as novel target drug delivery systems and leading chromatographic isolation approaches. Electrophoresis 2021. [PMID: 34791693 DOI: 10.1002/elps.202100124] [Reference Citation Analysis]
11 Cano-Cortes MV, Altea-Manzano P, Laz-Ruiz JA, Unciti-Broceta JD, Lopez-Delgado FJ, Espejo-Roman JM, Diaz-Mochon JJ, Sanchez-Martin RM. An effective polymeric nanocarrier that allows for active targeting and selective drug delivery in cell coculture systems. Nanoscale 2021;13:3500-11. [PMID: 33560282 DOI: 10.1039/d0nr07145e] [Reference Citation Analysis]
12 Zhang L, Li Z, Ye X, Chen Z, Chen ZS. Mechanisms of thrombosis and research progress on targeted antithrombotic drugs. Drug Discov Today 2021:S1359-6446(21)00210-5. [PMID: 33895314 DOI: 10.1016/j.drudis.2021.04.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kwon YM. Targeted delivery of thrombolytic enzymes. Bioimpacts 2021;11:85-6. [PMID: 33842278 DOI: 10.34172/bi.2021.15] [Reference Citation Analysis]
14 Wang Y, Chen H, Sheng R, Fu Z, Fan J, Wu W, Tu Q, Guo R. Synthesis and Bioactivities of Marine Pyran-Isoindolone Derivatives as Potential Antithrombotic Agents. Mar Drugs 2021;19:218. [PMID: 33921137 DOI: 10.3390/md19040218] [Reference Citation Analysis]
15 Gu B, Huang Y, Manchester EL, Hughes AD, Thom SAM, Chen R, Xu XY. Multiphysics Modelling and Simulation of Thrombolysis via Activated Platelet-Targeted Nanomedicine. Pharm Res 2022. [PMID: 35044591 DOI: 10.1007/s11095-021-03161-2] [Reference Citation Analysis]
16 Huang Y, Gu B, Salles-Crawley II, Taylor KA, Yu L, Ren J, Liu X, Emerson M, Longstaff C, Hughes AD, Thom SA, Xu XY, Chen R. Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy. Sci Adv 2021;7:eabf9033. [PMID: 34078604 DOI: 10.1126/sciadv.abf9033] [Cited by in F6Publishing: 1] [Reference Citation Analysis]